White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies
Executive Summary
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
You may also be interested in...
Individualized Therapeutics Could Get Boost From NIH Platform Gene Therapy Pilot
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Regenerative Medicine Is Here: New Payment Models Key To Patient Access
Potentially curative regenerative medicine therapies are no longer theoretical, but instead have become reality. As more and more gene, cell and tissue-based therapies reach the market, the need for payment solutions is becoming more pressing. The Alliance for Regenerative Medicine has consulted with payers and other stakeholders to consider the barriers to alternative payment models and look at possible solutions.
Need a specific report? 1000+ reports available
Buy Reports